Trichostatin A (TSA) 化学構造
分子量: 302.4

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare HDAC Inhibitors
    HDAC製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法
  • Trichostatin A (TSA)のメカニズム

製品の説明

生物活性

製品説明 Trichostatin A (TSA) は、HDAC阻害剤で、IC50 が ~1.8 nM。
ターゲット

HDAC

IC50

~1.8 nM [1]

In vitro試験 Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HEK 293 NHPic3hHfW6ldHnvckBCe3OjeR?= M4nmSFAvP87:TR?= NWPwNnhpOjSq M1rEXIV1cGGwb3y= MULlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm MVGyOVc5PzB5OR?=
TE13 M2DvN2Z2dmO2aX;uJGF{e2G7 MnrhNE4{|ryP MofGNlRp NXu2NHdCfXBvcnXneYxifGW|IGLBV3NHPUFibHX2[Yw> MmXpNlU2Pzl4NkW=
TE13 NVnrbnd5SXCxcITvd4l{KEG|c3H5 NIDWWlYxNjQQvF2= NFvpPWMzPGh? M3X1RYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MmLMNlU2Pzl4NkW=
MEFs NUfBbotoTnWwY4Tpc44hSXO|YYm= MnfJOe69VQ>? MmrZNVZp Mo\WbY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v NV;RbFd6OjV2OEK2N|Q>
SW480  MUjGeY5kfGmxbjDBd5NigQ>? NUS5PG5HOC5zzszN NIfWeoc1QGh? MkjZSG1UVw>? M2TIRZJmfmW{c3XzJGVOXA>? M1;SW|I2PDN2OUm3
PC3  NGDGSVFHfW6ldHnvckBCe3OjeR?= NX;2OXRtOC5zzszN NEiyd4g1QGh? Ml\3SG1UVw>? NYjuTldbemW4ZYLz[ZMhTU2W NETXT|UzPTR|NEm5Oy=>
SW480  NHvXbGtHfW6ldHnvckBCe3OjeR?= MVywMlHPxE1? NGK2cFg1QGh? NVvnUWJpTE2VTx?= NWm2NYdt[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u NF7oO4MzPTR|NEm5Oy=>
PC3  MX;GeY5kfGmxbjDBd5NigQ>? NWrBWWFzOC5zzszN NFvtXI41QGh? M4HTOGROW09? NXzvU3NM[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MWGyOVQ{PDl7Nx?=
SW480  MmfkSpVv[3Srb36gRZN{[Xl? NF\wOFkxNjIQvF2= MmTKOFhp NVPMRlZuTE2VTx?= MnHCbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NVzHVZVwOjV2M{S5PVc>
PC3  MWDGeY5kfGmxbjDBd5NigQ>? M3zaTFAvOc7:TR?= MXy0PIg> MknPSG1UVw>? MV7pcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz MXSyOVQ{PDl7Nx?=
A431 MkW2RZBweHSxc3nzJGF{e2G7 M3jPRlIwOTBxNUCvNVAxdk1? M{PGTVQ5cA>? NWf6UFkzTE2VTx?= NXTIdox3cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To NV7OeI5OOjV|N{GwOlk>
A431 NV\neGI6TnWwY4Tpc44hSXO|YYm= NFjsVow2OG6P NHnF[mgzNzZxMUKvNlRp M3\CcmROW09? M37oWoFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= M{LHV|I2OzdzME[5
MDA-MB-231 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrwfFYxNTZyMH7N NUHzVWx4OjSq NU\5So5yTE2VTx?= NFG4PYtKSzVyIH;mJFExOG6P MU[yOVE6Ojd{MR?=
MCF7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G3c|AuPjBybl2= MVuyOIg> MVTEUXNQ MXLJR|UxKG:oIEe1cm0> MVqyOVE6Ojd{MR?=
SKOV-3 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGy[|gyNTFyzszN NUXVepIzOjSq NHnLUItFVVOR M{iwTGlEPTBib3[gOU43|ryP MWiyOVE3QTR7MR?=
A549 NIGzZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDpUGEyNTFyzszN MXqyOIg> NFXrTHhFVVOR NFPQUFhKSzVyIH;mJFMvOs7:TR?= NXW1N5RROjVzNkm0PVE>
SKOV-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfmNE4yNTIQvF2= NEPpSW81QGh? MX;EUXNQ MVLJR|UxKG:oIECuO:69VQ>? M4HCc|I2OTZ7NEmx
A549 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu0T5oxNjFvMd88US=> NVTp[|BwPDiq MYfEUXNQ NFL3PI5KSzVyIH;mJFAvOjkQvF2= NX;ydHVkOjVzNkm0PVE>
SKOV-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKwMlAyNTBwOd88US=> M2TIXlczcA>? NEm2bHNFVVOR M{HBS2lEPTBib3[gNE4{Os7:TR?= NX33bFRTOjVzNkm0PVE>
A549 NU[zO2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmwMlAyNTBwOd88US=> NW\nUIRbPzKq NFrQ[ndFVVOR NVLMSolbUUN3MDDv[kAxNjB4zszN NGDvR4kzPTF4OUS5NS=>
HeLa MnPzSpVv[3Srb36gRZN{[Xl? NYT4d5ZwOjVybl2= M2nyflE3cA>? MUDEUXNQ M1z3c4lv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= MYWyOVEyPjZ6OB?=
CNE2 NXPyPYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[zPVExOC14MEDuUS=> M3\DfFI1NzR6L{eybC=> MVHpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1TQR|I1QTZ7OUCx
PC3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LtbFExOC1zMECwcm0> M{jaNFI1cA>? M4Txc2lEPTBib3[gN|Axdk1? M2\QTVI1QDV2NkW4
LNCaP MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn4O5VyOTByLUGwNFBvVQ>? NIPvPZEzPGh? M1P3XGlEPTBib3[gN|Axdk1? MXGyOFg2PDZ3OB?=
HeLa  NIjIemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i2TVLPxE1? MmPDOFhp Mn;J[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= MkG3NlQ5PDZzM{W=
HMEC-1  NEDQfHdHfW6ldHnvckBCe3OjeR?= M2Xi[lMxOG6P NUDOVWxUOjSq NX3GU|ZIcW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? MVOyOFcyODZ|MR?=
HeLa NGLsOFBHfW6ldHnvckBCe3OjeR?= Mny3NY1O M1rVSFAvPWh? MWjhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? MnzWNlQ4ODd2N{S=
ACP02 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXJNlUxNzN3MD:1NFBvVQ>? MW[yOIg> M2fVcIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? M{HCbFI1PjZ6NUS3
ACP03 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLUOJMzPTBxM{WwM|UxOG6P NHWxR|MzPGh? NYDTbnFN\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MkH4NlQ3Pjh3NEe=
U87 GBM NFfkb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKxNXIyODBxM{CwM|UxOCCwTR?= M2nib|czKGh? M1m3c|ExOCViZYToZY5wdA>? MWjy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= Mn\hNlQ1PjR6NEG=
U87 GBM MkiwSpVv[3Srb36gRZN{[Xl? NFT6SYIyODBxNUCwJG5u NIWzXWE1QCCq MlfWNVAxLSCndHjhco9t M3TkOGlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? NWK1VIhkOjR2NkS4OFE>
RPE NFPBV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSwMlIwOC52L{CuPE8yKM7:TR?= MYqyOE81QC95MjDo MXHEUXNQ NXy2NG5HcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? MWOyOFQ2PjZyMh?=
HT29  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLlNVgxKG6P MYi3NkBp MXHJR|UxKG:oIEG4NEBvVQ>? MoToNlQ{Pjh{NkW=
hMSCs NGHUOXpHfW6ldHnvckBCe3OjeR?= MlvJOk4zPSCwTR?= MkDNNlQhcA>? NYfsS3FkTE2VTx?= NYrMbG56e3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> NWfDbmNwOjR|MUKzOVY>
Huh7  NHLGTGdHfW6ldHnvckBCe3OjeR?= MX:wMlEwOC53L{GuNEDPxE1? MnTsNlRp MVfzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? M1zMV|I1OjZ7Nkey
SKOV3 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG0fmhoOC5yNT2yJO69VQ>? NIK1WJEyOC9{ND:0PEBp NYrwcWtyTE2VTx?= M2H5TI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NGjwZ2kzPDJ{M{iwNS=>
A2780 M2PuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3njXFAvODVvMjFOwG0> NWHITmlqOTBxMkSvOFghcA>? M2e4RWROW09? NYDuUmFNdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M1;oS|I1OjJ|OECx
SRA01/04  NILNWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LkVFAvOiEQvF2= MV20PEBp MorrSG1UVw>? MVvzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MkOxNlQyPTd6N{i=
HLEB3 NVHyO|BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6T3kxNjJizszN M4jufVQ5KGh? M1fJdGROW09? M{i2ZZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NH;jVWIzPDF3N{i3PC=>
SRA01/04  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvNcWMxNjRxMD64JO69VQ>? M3zaVFQ5KGh? M4DK[GROW09? MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVuyOFE2Pzh5OB?=
HLEB3 M{\Rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjHbGYxOC52L{CuPEDPxE1? MVu0PEBp NGC1XVZFVVOR NYT5ZVlwcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M{Li[lI1OTV5OEe4
HCT116 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMlIh|ryP MVWxNkBp MXLlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= MmTkNlQyOjJ{M{G=
CA46 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjDXIM5Oy94L{GyM|I1NzR6IH7N MUm0PEBp M2fHeIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? NILpRZMzPDB4NEm1NS=>
PMNs NGqyZZRHfW6ldHnvckBCe3OjeR?= MVSzNEBvVQ>? NVr6WIp5PDhiaB?= M4XkdolvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> NVrqfGhLOjN7OEi2NVc>
H1299 NWezTWhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\wSVHDqM7:TdMg NV;kfI9QOjRxNEivO|IhcA>? MWnleIhidm:u MXnpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> MYGyN|kyPjZyOR?=
A549 NEe0VGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjsNE4zPS9yLkWvNUDPxE1? MVuyOE81QC95MjDo M1r0[4V1cGGwb3y= MUHpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MXuyN|g3Pzl7MR?=
H1299 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjyfpFYOC5{NT:wMlUwOSEQvF2= MYKyOE81QC95MjDo Mmnw[ZRp[W6xbB?= NGWzNFhqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NEn3VHIzOzh4N{m5NS=>
A549 MV7BdI9xfG:|aYOgRZN{[Xl? MnHjNE42NzFizszN MnrKOFghcA>? NEG4NoZmfGijbn;s MYTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Ml;RNlM5Pjd7OUG=
H1299 NHq1U3RCeG:ydH;zbZMhSXO|YYm= NULMbJEzOC53L{Gg{txO NULvcmNDPDhiaB?= NULsW3lT\XSqYX7vcC=> MULpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MU[yN|g3Pzl7MR?=
SUM149PT NUDPeWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[yNk84NjVxMUCg{txO M3fKeFQ5KGh? NX32UIFuTE2VTx?= NVz5U5hJcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= M16ySlI{Pzl{NkO4
SUM190PT NX[2d3BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe1NE8yODBxMkWwJI5O NHmyflU1QCCq MWHEUXNQ M4nhdYlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? MlXSNlM4QTJ4M{i=
HCT1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fm[|AvOi9zLkCvOU4xKM7:TR?= MXqxNk8zPC9|Nj:0PEBp NGjUflhqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MUKyN|c4ODByMB?=
Lovo Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jWcFAvOi9zLkCvOU4xKM7:TR?= M1jvWlEzNzJ2L{O2M|Q5KGh? M{HDZolv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NInqWJczOzd5MECwNC=>
AGS NF;I[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XMd|AvODF3LUGg{txO MWi3NkBp M4rvfIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 Ml\DNlM4PDVyMkS=
Huh7 NWX6Voo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnyUncyKM7:TR?= M4TRN|I1KGh? M4HwTmROW09? MkCzdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NWLZNHFFOjN4NEO5N|M>
ECC1 M1;BRmZ2dmO2aX;uJGF{e2G7 MmX3OVAxKG6P NGq1bWw2KGR? NVi3fI13TE2VTx?= NVvXc3pScW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= Moq3NlM2OzB5Nkm=
HEC1A M1\xbWZ2dmO2aX;uJGF{e2G7 MnXCOVAxKG6P NHLQN3I2KGR? MXnEUXNQ NVPy[ZpOcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NFSwUpEzOzV|MEe2PS=>
EN1 NXjqS4Z7TnWwY4Tpc44hSXO|YYm= MlPOOVAxKG6P M{LjclUh\A>? NVTWfWEyTE2VTx?= MVzpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NVfBZmZmOjN3M{C3Olk>
MFE296 MnHBSpVv[3Srb36gRZN{[Xl? NVfYcVFvPTByIH7N NELCO2o2KGR? NVn1W|U5TE2VTx?= MYXpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NFHzZXIzOzV|MEe2PS=>
HASMCs MY\GeY5kfGmxbjDBd5NigQ>? M3HO[FAuPTByIH7N NEn2TZI3KGR? MoPF[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> M3TONVI{PTF6NE[3
U373 MmXzSpVv[3Srb36gRZN{[Xl? MYCwMlI2NzBwNT:xJO69VQ>? M3W3bFI1KGh? M173Solv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF M4PqbVI{PDd2MUex
ARN8  M2jlb2Z2dmO2aX;uJGF{e2G7 MnTYNE4xPS1{IN88US=> MXKyOEBp MVny[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NIf2dI8zOzR5MEW0NC=>
MCF7 MYrGeY5kfGmxbjDBd5NigQ>? MoqyNE4xPS1{IN88US=> MXSyOEBp MXXy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> MlrONlM1PzB3NEC=
H1299  MV\GeY5kfGmxbjDBd5NigQ>? M4TPV|AvOzQkgKOxxsDDvU1? M3SxU|I1NzR6IHi= MnrLSG1UVw>? NUC0bIh1cW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> M4GwUVI{PDZzOUe1
H1299 MXPGeY5kfGmxbjDBd5NigQ>? M4\QSVAvPSEQvF2= MVG0PEBp MXfEUXNQ NX\XbI83cW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MWCyN|Q3OTl5NR?=
H1299 MoPESpVv[3Srb36gRZN{[Xl? NYHHbnZJOC53IN88US=> MXK0PEBp NV;6UYZNTE2VTx?= NELPdHJqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= NYmwPJB2OjN2NkG5O|U>
MG-63  Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTXWpFPOC5|IN88US=> M4nQbVEzNTl4IHi= NGT2OZZFVVOR M2fESYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= NFnNOZEzOzR3MUixOy=>
LM8 NXTydFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e4SlAvOyEQvF2= NFLX[pMyOi17NjDo Mk\ESG1UVw>? MoDlbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MlzsNlM1PTF6MUe=
K562 M4TibGZ2dmO2aX;uJGF{e2G7 MlHoNE42KM7:TR?= NIT2TngzPCCq Mn[4[ZRp[W6xbB?= NUC5[IUz\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? NGjiN3AzOzR|MEm1Oy=>
HEL MWXGeY5kfGmxbjDBd5NigQ>? MV2wMlUh|ryP M2XiWFI1KGh? NH7Dc|FmfGijbn;s MUXk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> M1u1dVI{PDNyOUW3
HL60 NGmzXJpCeG:ydH;zbZMhSXO|YYm= MY[xJO69VQ>? NXuzbVl{OjRiaB?= MXPpcoR2[2W|wrDj[YxtKGSnYYTo Mk\1NlM1ODB3MUm=
KG1 NEDIZphCeG:ydH;zbZMhSXO|YYm= NGXvfVUyKM7:TR?= NHnOUJQzPCCq NILTPJlqdmS3Y3XzxsBk\WyuIHTlZZRp MmKxNlM1ODB3MUm=
Kazumi MlPsRZBweHSxc3nzJGF{e2G7 NUf4bFRNOSEQvF2= M4rzXFI1KGh? MXzpcoR2[2W|wrDj[YxtKGSnYYTo MnXhNlM1ODB3MUm=
K562 NGPJXHFCeG:ydH;zbZMhSXO|YYm= Mln2NUDPxE1? MUOyOEBp NV\ndVVwcW6mdXPld:Kh[2WubDDk[YF1cA>? NHvq[pQzOzRyMEWxPS=>
THP1 M1HTW2Fxd3C2b4Ppd{BCe3OjeR?= NYXTW3EzOSEQvF2= NGfyZoozPCCq NYT6U3VUcW6mdXPld:Kh[2WubDDk[YF1cA>? NGT4R4YzOzRyMEWxPS=>
SH-SY5Y M1XN[WZ2dmO2aX;uJGF{e2G7 NIO3SnUzPTBibl2= M2DOPVE3KGh? MUXjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 M4nmSVI{OzJ4NEKy
HEK293 MonpSpVv[3Srb36gRZN{[Xl? MmTKNUDDvU4EoB?= NUHMd4lrOThiaNMg MnTObY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? NEC5b5czOzJ6NEi0PC=>
HTK NYDneVhUTnWwY4Tpc44hSXO|YYm= NFvufG81ODBibl2= NHTW[4Q4OiCq NHLQWJlqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v M3vBflI{Ojh2MECy
HTK MW\GeY5kfGmxbjDBd5NigQ>? NIrCO|UyODBvOECwcm0> MmXUO|IhcA>? NYrrdIg2[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= MVeyN|I5PDByMh?=
Caco-2  MmD4SpVv[3Srb36gRZN{[Xl? MVqxJOK2VcLi NVjmT5AzOjRiaB?= M4HyUYRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= MnjPNlMyQTVyN{C=
HeLa NEfXSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfkUHYyODBibl2= M4D3S|I1KGh? MX3EUXNQ MonYTWM2OCCxZjCxNFBvVQ>? M{G1W|I{OTZ3N{S4
HeLa Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC0NEBvVQ>? NEjvdIU1QCCq NWTESY94TE2VTx?= MkLITWM2OCCxZjC0NI5O MonENlMyPjV5NEi=
HeLa MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXvNlAhdk1? NX3PXo0{PzJiaB?= NGDuXWZFVVOR NIXwdWtKSzVyIH;mJFIxdk1? MYqyN|E3PTd2OB?=
HeLa NXPKV2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexNE8{OC93MDDuUS=> M3fhOVczKGh? Mn\SSG1UVw>? MVfpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= M33RN|I{OTZ3N{S4
MDA-MB-231 NXjFb|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\hOYp6OjVvNECwJI5O MXG0PEBp M{\teWlEPTBib3[gNlY{NjKwTdMg NVzXZnQyOjNyNUWxPVg>
MCF-7  NF24U|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq2NlUuPDByIH7N NVvreol7PDhiaB?= MWDJR|UxKG:oIEKyNE41dk1? MkWwNlMxPTVzOUi=
ECC-1  M3XxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;pelJ6OTByIH7N M2mwdVI1KGh? NFT6U|VmfGijbn;s MYHpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? NUnMTmZEOjNyMki4NFM>
HEC-1A Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfLWo57OTByIH7N NVjocFZkOjRiaB?= Mojp[ZRp[W6xbB?= M1zt[4lv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= NXGzdHJxOjNyMki4NFM>
NHAC-kn NWmweHZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:xNE8yODBxNUCwJI5O M3L5blEzKGh? M3K4bmROW09? M3zEN2lEPTBib3[gOVAxdk1? NWrQ[HRkOjNyMUe4O|E>
A549 NVjsO3V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13Lb|I2OCCwTR?= NGHke3Y3NTd{IHi= M3TacmROW09? Mlj4Z4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> MWGyNlk6PDd6MB?=
MG-63 NXrtdpU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTpN|AxKG6P NWi3OoFEOTJiaB?= NIDaNVJFVVOR NGTEXW5qdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn NVLwXYxLOjJ5OUmzN|g>
MG-63 NYXMcmo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXvN|AxKG6P NX2yeXBHOjRiaB?= M1vSZ2ROW09? NWHVZ3VzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= MYiyNlc6QTN|OB?=
MG-63 NFrWUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKzNFAhdk1? M3HzWlQ5KGh? M2HuNmROW09? NHLUZYFqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn MkTvNlI4QTl|M{i=
HL60  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInwbpIyPTBvM{WwJI5O NELBPG0zPCCq M13ZV4lv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NEnYW4wzOjd3M{ezPS=>
U937 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKxOVAuOzVyIH7N MorHNlQhcA>? NGPBflBqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O NYTxZmFUOjJ5NUO3N|k>
SCC-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jGeFIxOC1|MkCwJI5O MXyxNk8zPC92ODDo NWL3T3lFTE2VTx?= Ml61bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhW0OFLU[gZ4VtdHNiaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MoPUNlI2PTJ|MkG=
U87  M4\xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGwNVAxNTNyMDDu[y=> MUiyOEBp MYrpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO|ImKCCjdDCyNFBv\w>? MYeyNlI4ODh2OR?=
K562 M3vaOWZ2dmO2aX;uJGF{e2G7 MXexJO69VQ>? M3jBNlEzKGh? NUPKSFE4TE2VTx?= MkHt[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MkX2NlIyPzlzOUi=
Reh MXzGeY5kfGmxbjDBd5NigQ>? NHnsd5QxNjNxMTFOwG0> NV3zXJRkOTJiaB?= MYTEUXNQ NUD1cIl5\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> MYmyNlE4QTF7OB?=

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

In vitro HDAC activity Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.

細胞アッセイ:

[1]

細胞株 MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
濃度 Dissolved in absolute ethanol, final concentrations ~10 μM
反応時間 96 hours
実験の流れ

Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.

動物実験:

[1]

動物モデル Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
製剤 Dissolved in DMSO
投薬量 ~5 mg/kg/day
投与方法 Injection s.c.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Trichostatin A (TSA) SDF
分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 23 mg/mL (76.05 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (R,2E,4E)-6-(4-(dimethylamino)benzoyl)-N-hydroxy-4-methylhepta-2,4-dienamide

文献中の引用 (20)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related HDAC 阻害剤

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • HPOB

    HPOB is a potent, selective HDAC6 inhibitor with IC50 of 56 nM, >30-fold selectivity over other HDACs.

  • Panobinostat (LBH589)

    Panobinostat (LBH589)は、MOLT-4とReh細胞のための新しい幅広いスペクトルHDAC阻害剤で、IC50 がそれぞれ 5 と 20 nMになる。Phase 4

  • Vorinostat (SAHA, MK0683)

    Vorinostat (SAHA, MK0683)ボリノスタット(SAHA)は、86nM未満のIC50による強力なクラスIおよびIIヒストン脱アセチル化酵素(HDAC)阻害剤です。

  • Entinostat (MS-275)

    Entinostat (MS-275)は、HDAC1とHDAC3のHDAC阻害剤で、IC50 がそれぞれ 0.51 μM と 1.7 μMです。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は、強力なヒストン脱アセチル化酵素1と2つの(HDAC1とHDAC2)阻害剤で、 IC50 がそれぞれ 36 nM と 47 nMです。

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is a HDAC inhibitor, with an IC50 of 0.08μM for HDAC3, exhibits > 200-fold selectivity over other HDAC.

最近チェックしたアイテム

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ